RETA 40mg

RETA 40mg
£140.00

(NOT FOR HUMAN CONSUMPTION RESEARCH USE ONLY) 

Reta (LY3437943)

is an investigational synthetic peptide and the first "triple agonist" being developed to treat obesity and type 2 diabetes. Developed by Eli Lilly, it targets three different hormone receptors simultaneously—GLP-1, GIP, and glucagon—earning it the nickname "Triple G". 

 

Mechanism of Action

Unlike earlier treatments like semaglutide (single agonist) or tirzepatide (dual agonist), retatrutide's triple-action approach targets multiple metabolic pathways: 

  • GLP-1: Stimulates insulin, slows stomach emptying, and suppresses appetite.
  • GIP: Enhances insulin release and fat metabolism while further reducing food desire.
  • Glucagon: Increases energy expenditure and fat oxidation (fat burning), potentially offering a metabolic boost beyond standard hunger suppression. 

 

Clinical Trial Results

Early phase data suggests retatrutide may be more effective than currently approved medications: 

  • Weight Loss: In Phase 2 trials, the highest dose (12 mg weekly) led to an average weight loss of 24.2% after 48 weeks—nearly a quarter of body weight.
  • Topline Phase 3 (TRIUMPH-4): Results released in late 2025 showed record-breaking weight loss of up to 28.7% (average 71.2 lbs) at 68 weeks and a 75.8% reduction in knee osteoarthritis pain.
  • Liver Health: In a substudy, roughly 86%–90% of patients on high doses achieved normal liver fat levels, potentially resolving metabolic dysfunction-associated steatotic liver disease (fatty liver). 

 

Status and Safety

 

  • Common Side Effects: Similar to other incretin-based drugs, side effects are primarily gastrointestinal, including nausea, vomiting, diarrhea, and constipation. Dose-dependent increases in heart rate have also been observed, peaking at 24 weeks.